Antibody blockade of Jagged1 attenuates choroidal neovascularization - Nature Communications
Nature· 7 days agoCurrent treatment for neovascular age-related macular degeneration (nAMD) does not help all patients. Here, the authors show that using ...
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib...
Morningstar· 4 days ago“With the ODYSSEY clinical trial now open for enrollment, we are excited to continue exploring the potential of CLS-AX to provide an effective and less burdensome treatment
Visgenx Appoints William Pedranti as Chief Executive Officer
FOX 4 Kansas City· 10 hours agoVisgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, today announced the appointment of William Pedranti, J.D., as Chief Executive Officer ...
Alkeus Announces $150 Million Series B Financing, Supporting Rapid Registration Path for...
Morningstar· 10 hours agoAlkeus Pharmaceuticals announced today that it has raised a $150 million Series B financing to support the registration and launch of gildeuretinol (ALK-001), a potential disease-modifying, ...
Prevent the Leading Cause of Vision Loss With 5 Daily Habits
Woman's World via Yahoo News· 4 days agoBonus: Season your veggies with delicious saffron, which, according to the Italian Journal of...
Iveric bio, Still A 5+% Opportunity (NASDAQ:ISEE)
Seeking Alpha· 6 days ago(OTCPK:ALPMF). The company's valuation is driven by its lead drug Avacincaptad pegol, which is an investigational drug for the treatment of geographic...
EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in...
Benzinga· 9 hours ago"We are delighted to report the completion of enrollment in the Phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential nine-month treatment for NPDR," said Nancy.
Kodiak Sciences to Present at Upcoming Investor Conferences
WWNY - WNYF Watertown· 6 days agoPALO ALTO, Calif., May 30, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics ...
Cambridge biotech raises $150 million and rehires founder of Vertex - The Boston Globe
The Boston Globe· 10 hours agoAlkeus Pharmaceuticals also said it has rehired one of the industry’s most prominent figures to help...
Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
Zacks via Yahoo Finance· 6 days agoKodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications....
Yahoo Web Search
Related topics
Treatment Macular Degeneration
Trending Now
